Literature DB >> 23858473

EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.

Emilie A Bard-Chapeau1, Jayantha Gunaratne, Pankaj Kumar, Belinda Q Chua, Julius Muller, Frederic A Bard, Walter Blackstock, Neal G Copeland, Nancy A Jenkins.   

Abstract

Ecotropic viral integration site-1 (EVI1) is an oncogenic zinc finger transcription factor whose expression is frequently up-regulated in myeloid leukemia and epithelial cancers. To better understand the mechanisms underlying EVI1-associated disease, we sought to define the EVI1 interactome in cancer cells. By using stable isotope labeling by amino acids in cell culture (SILAC)-based quantitative proteomics, we could confidently assign 78 proteins as EVI1-interacting partners for FLAG-tagged EVI1. Subsequently, we showed that 22 of 27 tested interacting proteins could coimmunoprecipitate with endogenous EVI1 protein, which represented an 81.5% validation rate. Additionally, by comparing the stable isotope labeling by amino acids in cell culture (SILAC) data with high-throughput yeast two hybrid results, we showed that five of these proteins interacted directly with EVI1. Functional classification of EVI1-interacting proteins revealed associations with cellular transcription machinery; modulators of transcription; components of WNT, TGF-β, and RAS pathways; and proteins regulating DNA repair, recombination, and mitosis. We also identified EVI1 phosphorylation sites by MS analysis and showed that Ser538 and Ser858 can be phosphorylated and dephosphorylated by two EVI1 interactome proteins, casein kinase II and protein phosphatase-1α. Finally, mutations that impair EVI1 phosphorylation at these sites reduced EVI1 DNA binding through its C-terminal zinc finger domain and induced cancer cell proliferation. Collectively, these combinatorial proteomic approaches demonstrate that EVI1 interacts with large and complex networks of proteins, which integrate signals from various different signaling pathways important for oncogenesis. Comprehensive analysis of the EVI1 interactome has thus provided an important resource for dissecting the molecular mechanisms of EVI1-associated disease.

Entities:  

Keywords:  EVI1 complex locus mass spectrometry; MDS1

Mesh:

Substances:

Year:  2013        PMID: 23858473      PMCID: PMC3732971          DOI: 10.1073/pnas.1309310110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  In-gel digestion for mass spectrometric characterization of proteins and proteomes.

Authors:  Andrej Shevchenko; Henrik Tomas; Jan Havlis; Jesper V Olsen; Matthias Mann
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Affinity-purification mass spectrometry (AP-MS) of serine/threonine phosphatases.

Authors:  Ginny I Chen; Anne-Claude Gingras
Journal:  Methods       Date:  2007-07       Impact factor: 3.608

3.  Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.

Authors:  Meera Nanjundan; Yasuhisa Nakayama; Kwai Wa Cheng; John Lahad; Jinsong Liu; Karen Lu; Wen-Lin Kuo; Karen Smith-McCune; David Fishman; Joe W Gray; Gordon B Mills
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

4.  Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells.

Authors:  Leopoldo Laricchia-Robbio; Raffaella Fazzina; Donglan Li; Ciro R Rinaldi; Kisaly K Sinha; Soumen Chakraborty; Giuseppina Nucifora
Journal:  Mol Cell Biol       Date:  2006-09-05       Impact factor: 4.272

5.  Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung.

Authors:  Yong-Woo Choi; Jin Soo Choi; Long Tai Zheng; Yun Jeong Lim; Hyoung Kyu Yoon; Yeul Hong Kim; Young-Pil Wang; Young Lim
Journal:  Lung Cancer       Date:  2006-11-15       Impact factor: 5.705

6.  Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.

Authors:  Vitalyi Senyuk; Kislay K Sinha; Donglan Li; Ciro R Rinaldi; Sastry Yanamandra; Giuseppina Nucifora
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

7.  Cloning and characterization of mCtBP2, a co-repressor that associates with basic Krüppel-like factor and other mammalian transcriptional regulators.

Authors:  J Turner; M Crossley
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

8.  ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.

Authors:  Shuhei Matsuoka; Bryan A Ballif; Agata Smogorzewska; E Robert McDonald; Kristen E Hurov; Ji Luo; Corey E Bakalarski; Zhenming Zhao; Nicole Solimini; Yaniv Lerenthal; Yosef Shiloh; Steven P Gygi; Stephen J Elledge
Journal:  Science       Date:  2007-05-25       Impact factor: 47.728

9.  The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.

Authors:  M Kurokawa; K Mitani; K Irie; T Matsuyama; T Takahashi; S Chiba; Y Yazaki; K Matsumoto; H Hirai
Journal:  Nature       Date:  1998-07-02       Impact factor: 49.962

Review 10.  The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.

Authors:  Rotraud Wieser
Journal:  Gene       Date:  2007-04-20       Impact factor: 3.688

View more
  22 in total

Review 1.  A mass spectrometry view of stable and transient protein interactions.

Authors:  Hanna G Budayeva; Ileana M Cristea
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

2.  Functional Proteomic Analysis of Repressive Histone Methyltransferase Complexes Reveals ZNF518B as a G9A Regulator.

Authors:  Verena K Maier; Caitlin M Feeney; Jordan E Taylor; Amanda L Creech; Jana W Qiao; Attila Szanto; Partha P Das; Nicholas Chevrier; Catherine Cifuentes-Rojas; Stuart H Orkin; Steven A Carr; Jacob D Jaffe; Philipp Mertins; Jeannie T Lee
Journal:  Mol Cell Proteomics       Date:  2015-02-13       Impact factor: 5.911

3.  Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.

Authors:  Danton Ivanochko; Levon Halabelian; Elizabeth Henderson; Pavel Savitsky; Harshika Jain; Edyta Marcon; Shili Duan; Ashley Hutchinson; Alma Seitova; Dalia Barsyte-Lovejoy; Panagis Filippakopoulos; Jack Greenblatt; Evelyne Lima-Fernandes; Cheryl H Arrowsmith
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

4.  Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.

Authors:  A Sayadi; J Jeyakani; S H Seet; C-L Wei; G Bourque; F A Bard; N A Jenkins; N G Copeland; E A Bard-Chapeau
Journal:  Oncogene       Date:  2015-08-03       Impact factor: 9.867

5.  EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer.

Authors:  Hwa-Ryeon Kim; Juhye Yim; Hye-Been Yoo; Seung Eon Lee; Sumin Oh; Sungju Jung; Chang-Il Hwang; Dong-Myung Shin; TaeSoo Kim; Kyung Hyun Yoo; You-Sun Kim; Han-Woong Lee; Jae-Seok Roe
Journal:  NAR Cancer       Date:  2021-06-17

6.  Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas.

Authors:  Jonathan J Lee; Lynette M Sholl; Neal I Lindeman; Scott R Granter; Alvaro C Laga; Priyanka Shivdasani; Gary Chin; Jason J Luke; Patrick A Ott; F Stephen Hodi; Martin C Mihm; Jennifer Y Lin; Andrew E Werchniak; Harley A Haynes; Nancy Bailey; Robert Liu; George F Murphy; Christine G Lian
Journal:  Clin Epigenetics       Date:  2015-06-09       Impact factor: 6.551

7.  Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.

Authors:  Emilie A Bard-Chapeau; Dorota Szumska; Bindya Jacob; Belinda Q L Chua; Gouri C Chatterjee; Yi Zhang; Jerrold M Ward; Fatma Urun; Emi Kinameri; Stéphane D Vincent; Sayadi Ahmed; Shoumo Bhattacharya; Motomi Osato; Archibald S Perkins; Adrian W Moore; Nancy A Jenkins; Neal G Copeland
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

8.  EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age.

Authors:  A Stevens; D Hanson; C de Leonibus; A Whatmore; R Donn; D J White; J Liu; M M van den Heuvel-Eibrink; V Saha; P E Clayton; S Meyer
Journal:  Blood Cancer J       Date:  2014-01-24       Impact factor: 11.037

Review 9.  Transcriptional network control of normal and leukaemic haematopoiesis.

Authors:  Jonathan I Sive; Berthold Göttgens
Journal:  Exp Cell Res       Date:  2014-07-08       Impact factor: 3.905

Review 10.  Functions of Prdm16 in thermogenic fat cells.

Authors:  Jeff Ishibashi; Patrick Seale
Journal:  Temperature (Austin)       Date:  2015-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.